Literature DB >> 7496774

Motion and shape perception in cerebral akinetopsia.

M Rizzo1, M Nawrot, J Zihl.   

Abstract

Motion cues serve many purposes in primate vision. Consequently, akinetopsia, a defect of movement perception due to cerebral lesions, would be expected to comprise a range of motion-related defects. To address this issue we explored further the perceptual profiles in akinetopsic subject L.M. who has motion perception deficits due to extensive bilateral lesions of the dorsolateral visual association cortex that spare primary visual cortex, area V1. We used several different experimental procedures. Using random-dot motion stimuli, we showed that L.M. can still perceive global coherent motion and discriminate motion direction, yet these abilities fail even at moderate levels of background noise. L.M. also viewed a two-frame apparent (phi) motion stimulus known as a Ternus display. Her performance on this test suggests defective 'long-range' apparent motion mechanisms. These results are clearly in agreement with previous reports. Additional experiments showed that L.M. can still perceive 2-D shape and 3-D structure-from-motion (SFM). However, like motion direction discrimination, these abilities broke down at moderate levels of moving and stationary noise. Surprisingly, L.M. also had trouble perceiving 2-D shapes defined by non-motion signals including 'on' and 'off' transients, dynamic and static binocular disparity, and static texture cues. Our findings highlight the role of the visual association cortex in extracting salient information from noise.

Entities:  

Mesh:

Year:  1995        PMID: 7496774     DOI: 10.1093/brain/118.5.1105

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  18 in total

Review 1.  Psychoanatomical substrates of Bálint's syndrome.

Authors:  M Rizzo; S P Vecera
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Visual field map clusters in human cortex.

Authors:  Brian A Wandell; Alyssa A Brewer; Robert F Dougherty
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-04-29       Impact factor: 6.237

3.  Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users.

Authors:  M Rizzo; C T J Lamers; C G Sauer; J G Ramaekers; A Bechara; G J Andersen
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

4.  Distracted driving in elderly and middle-aged drivers.

Authors:  Kelsey R Thompson; Amy M Johnson; Jamie L Emerson; Jeffrey D Dawson; Erwin R Boer; Matthew Rizzo
Journal:  Accid Anal Prev       Date:  2011-10-24

5.  Global versus local: double dissociation between MT+ and V3A in motion processing revealed using continuous theta burst transcranial magnetic stimulation.

Authors:  Peng Cai; Nihong Chen; Tiangang Zhou; Benjamin Thompson; Fang Fang
Journal:  Exp Brain Res       Date:  2014-09-09       Impact factor: 1.972

6.  Predictors of driving outcomes in advancing age.

Authors:  Jamie L Emerson; Amy M Johnson; Jeffrey D Dawson; Ergun Y Uc; Steven W Anderson; Matthew Rizzo
Journal:  Psychol Aging       Date:  2011-12-19

7.  Sex, drugs, and cognition: effects of marijuana.

Authors:  Beth M Anderson; Matthew Rizzo; Robert I Block; Godfrey D Pearlson; Daniel S O'Leary
Journal:  J Psychoactive Drugs       Date:  2010-12

8.  Naturalistic distraction and driving safety in older drivers.

Authors:  Nazan Aksan; Jeffrey D Dawson; Jamie L Emerson; Lixi Yu; Ergun Y Uc; Steven W Anderson; Matthew Rizzo
Journal:  Hum Factors       Date:  2013-08       Impact factor: 2.888

9.  First and second-order motion perception after focal human brain lesions.

Authors:  Matthew Rizzo; Mark Nawrot; Jondavid Sparks; Jeffrey Dawson
Journal:  Vision Res       Date:  2008-04-28       Impact factor: 1.886

10.  The role of human ventral visual cortex in motion perception.

Authors:  Sharon Gilaie-Dotan; Ayse P Saygin; Lauren J Lorenzi; Ryan Egan; Geraint Rees; Marlene Behrmann
Journal:  Brain       Date:  2013-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.